Imaging Diagnostic Systems (IDS) develops scanner for colon cancer:
This article was originally published in Clinica
Imaging Diagnostic Systems has started development of what it claims is a "revolutionary" laser scanner for the early detection of colon cancer. The scanner detects the fluorescence of molecules in the tumour region, to allow diagnosis of early-stage cancers on the surface of or within the colon wall. IDS believes the market is worth $500 million and hopes to capture 5% of new sales and 10% of replacement purchases. Colon cancer affects around 6% of the population in the US and Western Europe, with over 140,000 new diagnoses and 55,000 deaths per year.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.